Yuan Da Pharmaceuticals (00512) Globally innovative treatment for demodex blepharitis product has been approved for marketing by the China Macao Drug Regulatory Authority.

Wisdom Financial News APP News, Grand Pharma (00512) announced that the group's global innovative ophthalmic drug GPN01768 (TP-03, Lotilanadine eye drops, 0.25%) used for the treatment of Demodex blepharitis has recently been approved for listing by the Macao Special Administrative Region Government Pharmaceutical Supervision and Administration Bureau (Macao FDA). This is another important development for the group in the field of innovative ophthalmic treatment. The approval of this product by the Macao FDA lays the foundation for future approval in the Guangdong-Hong Kong-Macao Greater Bay Area, and is expected to further promote its landing in mainland China.